Journal article

Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617

Justin Ferdinandus, John Violet, Shahneen Sandhu, Rodney J Hicks, Aravind S Ravi Kumar, Amir Iravani, Grace Kong, Tim Akhurst, Sue Ping Thang, Declan G Murphy, Scott Williams, Michael S Hofman

European Journal of Nuclear Medicine and Molecular Imaging | SPRINGER | Published : 2020


PURPOSE: We analysed quantitative biomarkers derived from both baseline whole-body imaging and blood serum to identify prognostic markers in patients treated within the lutetium-177 prostate-specific membrane antigen (LuPSMA) phase 2 trial. METHODS: PET image analysis was carried out using whole-body segmentation quantifying molecular tumour volume (SUV > 3 threshold for PSMA, SUV > liver+2sd for fluorodeoxyglucose (FDG) including SUVmax and SUVmean. For baseline bone scans, EXINI bone scan index (BSI) was used to calculate the percentage of involved bone. Baseline alkaline phosphatase (ALP), lactate dehydrogenase (LDH), prostate specific antigen (PSA) and PSA doubling time were also used in..

View full abstract